These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9748634

  • 1. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition.
    Gils A, Vleugels N, Tobback K, Knockaert I, Declerck PJ.
    Biochim Biophys Acta; 1998 Sep 08; 1387(1-2):291-7. PubMed ID: 9748634
    [Abstract] [Full Text] [Related]

  • 2. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
    Gils A, Declerck PJ.
    J Biol Chem; 1997 May 09; 272(19):12662-6. PubMed ID: 9139722
    [Abstract] [Full Text] [Related]

  • 3. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
    Audenaert AM, Knockaert I, Collen D, Declerck PJ.
    J Biol Chem; 1994 Jul 29; 269(30):19559-64. PubMed ID: 8034724
    [Abstract] [Full Text] [Related]

  • 4. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A, Knockaert I, Declerck PJ.
    Biochemistry; 1996 Jun 11; 35(23):7474-81. PubMed ID: 8652525
    [Abstract] [Full Text] [Related]

  • 5. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
    Gils A, Lu J, Aertgeerts K, Knockaert I, Declerck PJ.
    FEBS Lett; 1997 Sep 29; 415(2):192-5. PubMed ID: 9350994
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B, Gils A, Vleugels N, Rabijns A, Declerck PJ.
    Biochem Biophys Res Commun; 2004 Aug 27; 321(3):746-51. PubMed ID: 15358169
    [Abstract] [Full Text] [Related]

  • 7. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q, Shaltiel S.
    BMC Biochem; 2003 Jul 08; 4():5. PubMed ID: 12848892
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties.
    De Taeye B, Compernolle G, Dewilde M, Biesemans W, Declerck PJ.
    J Biol Chem; 2003 Jun 27; 278(26):23899-905. PubMed ID: 12686544
    [Abstract] [Full Text] [Related]

  • 12. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1996 Oct 01; 241(1):38-46. PubMed ID: 8898886
    [Abstract] [Full Text] [Related]

  • 13. The importance of helix F in plasminogen activator inhibitor-1.
    Vleugels N, Gils A, Bijnens AP, Knockaert I, Declerck PJ.
    Biochim Biophys Acta; 2000 Jan 03; 1476(1):20-6. PubMed ID: 10606763
    [Abstract] [Full Text] [Related]

  • 14. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
    Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ.
    J Biol Chem; 2000 Mar 03; 275(9):6375-80. PubMed ID: 10692438
    [Abstract] [Full Text] [Related]

  • 15. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R, Petersen TE, Andreasen PA.
    Eur J Biochem; 2001 Feb 03; 268(3):673-85. PubMed ID: 11168406
    [Abstract] [Full Text] [Related]

  • 16. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H.
    J Mol Biol; 2001 Jan 26; 305(4):773-83. PubMed ID: 11162091
    [Abstract] [Full Text] [Related]

  • 17. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J.
    Mol Cancer Ther; 2003 Jan 26; 2(1):19-28. PubMed ID: 12533669
    [Abstract] [Full Text] [Related]

  • 18. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B, Verbeke K, Compernolle G, Biesemans W, Gils A, Declerck PJ.
    Biochem Biophys Res Commun; 2003 Aug 01; 307(3):529-34. PubMed ID: 12893254
    [Abstract] [Full Text] [Related]

  • 19. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H.
    J Biol Chem; 1990 Aug 05; 265(22):13029-35. PubMed ID: 1695900
    [Abstract] [Full Text] [Related]

  • 20. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
    Vleugels N, Leys J, Knockaert I, Declerck PJ.
    J Pharm Belg; 2000 Aug 05; 55(2):57-8. PubMed ID: 10842928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.